Philip Bonomi to Clinical Trials as Topic
This is a "connection" page, showing publications Philip Bonomi has written about Clinical Trials as Topic.
Connection Strength
1.826
-
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria. J Thorac Oncol. 2018 06; 13(6):748-751.
Score: 0.573
-
Historic evidence and future directions in clinical trial therapy of solid tumors. Oncology (Williston Park). 2006 May; 20(6 Suppl 5):10-8.
Score: 0.248
-
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Clin Lung Cancer. 2020 07; 21(4):295-307.
Score: 0.162
-
Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Stat Med. 1998 Mar 15-Apr 15; 17(5-7):781-96.
Score: 0.141
-
Epidermal growth factor receptor pathway. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S470-1.
Score: 0.085
-
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
Score: 0.084
-
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4606-12.
Score: 0.068
-
Other compounds and targets in non-small cell lung cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 10):S30-6.
Score: 0.060
-
Current strategies in the management of lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1667-8.
Score: 0.060
-
Novel treatments in non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):245-67.
Score: 0.053
-
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer. 2003 Aug; 41 Suppl 1:S43-8.
Score: 0.051
-
Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):78-86.
Score: 0.046
-
Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Oncology Group. Oncology (Williston Park). 1998 Jan; 12(1 Suppl 2):67-70.
Score: 0.035
-
Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol. 2016 09; 11(9):1387-96.
Score: 0.031
-
Treatment of stage III non-small cell lung cancer with thoracic radiation therapy and simultaneous platinum chemotherapy. Semin Oncol. 1994 Jun; 21(3 Suppl 6):101-8.
Score: 0.027
-
A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1988 Dec; 11(6):630-3.
Score: 0.019
-
Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study. Am J Clin Oncol. 1988 Feb; 11(1):1-2.
Score: 0.018
-
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4583-8.
Score: 0.017
-
Brief overview of combination chemotherapy in non-small-cell lung cancer. Semin Oncol. 1986 Sep; 13(3 Suppl 3):89-91.
Score: 0.016
-
Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Aug; 3(8):1079-85.
Score: 0.015
-
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71.
Score: 0.014
-
Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol. 1985 Dec; 12(4 Suppl 6):61-4.
Score: 0.004